Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ANAB | US
-1.02
-2.91%
Healthcare
Biotechnology
30/06/2024
04/10/2024
33.98
35.35
35.56
33.27
AnaptysBio Inc. a clinical-stage biotechnology company focuses in delivering immunology therapeutics. Its products include Imsidolimab an antibody that inhibits the interleukin-36 receptor which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032 an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences Inc. and changed its name to AnaptysBio Inc. in July 2006. AnaptysBio Inc. was incorporated in 2005 and is based in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
68.3%1 month
61.7%3 months
61.4%6 months
63.8%-
-
97.43
38.36
0.89
-1.30
20.63
-
-154.41M
1.03B
1.03B
-
-367.52
-
217.10
-214.89
16.47
26.45
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
7.56
Range1M
9.14
Range3M
16.92
Rel. volume
0.77
Price X volume
7.10M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
immatics biotechnologies GmbH | IMTX | Biotechnology | 10.86 | 1.12B | 3.23% | n/a | 0.00% |
Relay Therapeutics Inc. | RLAY | Biotechnology | 6.53 | 1.06B | 0.62% | n/a | 7.50% |
Autolus Therapeutics Plc | AUTL | Biotechnology | 3.98 | 1.06B | 0.25% | n/a | 54.69% |
Aurinia Pharmaceuticals Inc | AUPH | Biotechnology | 7.12 | 1.02B | 0.00% | n/a | 23.58% |
Pharvaris B.V | PHVS | Biotechnology | 18.2 | 982.94M | -0.66% | n/a | 0.04% |
Array BioPharma Inc | ARRY | Biotechnology | 6.45 | 979.92M | 0.62% | 67.30 | 117.68% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 4.23 | 941.03M | -2.98% | n/a | 29.02% |
Silence Therapeutics plc | SLN | Biotechnology | 18.64 | 933.49M | 1.30% | n/a | 0.16% |
Prothena Corporation plc | PRTA | Biotechnology | 16.86 | 906.74M | 1.08% | n/a | 2.08% |
Zymeworks Inc | ZYME | Biotechnology | 12.57 | 893.07M | 1.45% | n/a | 4.94% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.30 | 0.76 | Cheaper |
Ent. to Revenue | 20.63 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 97.43 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 61.42 | 74.67 | Par |
Debt to Equity | 38.36 | -1.82 | Expensive |
Debt to Assets | 0.89 | 0.26 | Expensive |
Market Cap | 1.03B | 3.73B | Emerging |